Adicet Bio (ACET) Current Deferred Revenue (2018 - 2021)

Adicet Bio's Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $4.8 million for Q4 2021.

• In Q4 2021, Current Deferred Revenue fell 65.63% year-over-year to $4.8 million; the TTM figure through Dec 2021 stood at $4.8 million (down 65.63% YoY), while the FY2021 annual figure was $4.8 million, down 65.63% from the prior year.
• Current Deferred Revenue for Q4 2021 stood at $4.8 million, down from $10.1 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $19.4 million in Q3 2020, with the low at $500000.0 in Q1 2018.
• The 4-year median for Current Deferred Revenue is $10.5 million (2019), against an average of $9.2 million.
• The sharpest annual moves came in 2020 and 2021: Current Deferred Revenue rose 27.17% in 2020, then sank 65.63% in 2021.
• Adicet Bio's Current Deferred Revenue stood at $500000.0 in 2018, then jumped by 2098.6% to $11.0 million in 2019, then increased by 27.17% to $14.0 million in 2020, then slumped by 65.63% to $4.8 million in 2021.
• Business Quant data shows ACET's Current Deferred Revenue at $4.8 million in Q4 2021, $10.1 million in Q3 2021, and $13.1 million in Q2 2021.